BioSpace News Archive

Yasheng Group, an agricultural and biotech company with U.S. headquarters in San Jose, California announced that HERB gained patent protection under the USPTO, entitled, “Method for Using Cyanobacteria to Collect Rare Earth Elements from Wastewater.”.

Tempo Bioscience, Inc., a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell derived cell products and affiliated cell-based services.

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced two upcoming poster presentations at the American Association for Cancer Research Meeting 2023 in Orlando, Florida.

Beacon Biomedical’s BeScreened-CRC blood test improves screening compliance and therefore the probability of survival while dramatically reducing the cost of treatment of CRC without the need for fecal collection.

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals.

RVL Pharmaceuticals plc today announced that the Company will release its fourth quarter and full year 2022 financial results and provide a commercial update on Monday, March 20, 2023, before U.S. financial markets open.

iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced that the first patients have been implanted in its STAR-VI international trial evaluating the safety and efficacy of MINIject® in conjunction with cataract surgery in patients with primary open-angle glaucoma.

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Aravive, Inc. today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023.